Solu Therapeutics
@Solu_Tx
Followers
30
Following
8
Media
84
Statuses
94
Solu Therapeutics is a precision-medicine focused company developing therapeutics to eliminate disease-driving cells.
Joined June 2023
Our team wrapped up the summer season with a well-deserved outing right in our backyard, enjoying the beauty of Boston Harbor! After a busy season of hard work and progress in the lab, it was great to unwind and celebrate together as we gear up for an exciting rest of the year.
0
0
0
Blood cancers like leukemia, lymphoma, and CMML start in the bone marrow or immune system. At Solu, we’re working to develop a therapy for CMML and other hematologic malignancies to bring new options to patients.
0
0
0
Our CEO Phil Vickers spoke with @BioTuesdays about how our CyTAC™ platform is exploring new possibilities in drug discovery, targeting cancers, immune disorders & inflammatory disease with limited treatment options. Read the full article:
biotuesdays.com
Closely held Solu Therapeutics is pairing heterobifunctional small molecules with monoclonal antibodies to develop therapeutic agents that eliminate disease-driving cells in cancer, immunology, and...
0
0
0
Today at #ACSFall2025: Catch our CSO Brandon Turunen presenting on “Recent Progress in the Discovery of Non-Degrading Molecular Glues and Heterobifunctional Molecules” at 2:35pm, in room 146B of the Walter E. Washington Convention Center
0
0
0
This #NationalInternDay, we’re proud to celebrate our interns, Amber and Emma. These future innovators are making a real contribution to our mission, and we’re inspired by their curiosity, energy, and fresh perspectives. Looking forward to all that you’ll accomplish!
1
0
0
Our CyTAC™ platform is helping us address immune-related diseases by selectively depleting pathogenic cells, without broadly suppressing the immune system. Learn more:
0
0
0
Meet Stephanie Wiltzius, Sr. Scientist & Lab Manager at Solu! Stephanie is an essential part of our biology research team, leading critical work across our pipeline and driving new target selection. We’re proud to have Stephanie on the team!
0
0
0
At Solu, we’re expanding what’s possible in drug discovery and development. Our unique platform links small molecules to antibodies designed to develop therapies with greater specificity and potency. Learn more:
0
0
0
#DYK: According to @LeukemiaRF, #CMML is about 2x more common in men than women. This #MensHealthAwarenessMonth, let’s raise awareness of blood cancers and work toward better outcomes for all patients living with hematologic malignancies. Learn more at
0
0
0
#BIO2025 is underway in Boston! We’re connecting with leaders across biotech to share the latest on our CyTAC™ and TicTAC™ platforms and our work in #oncology, #immunology, and pain. Reach out to meet with our team to learn more.
0
0
0
We’re excited to welcome Enda Moran, PhD, MBA, as Chief Operating Officer at Solu! Dr. Moran brings 30+ years of biomanufacturing and tech dev experience and will help drive our CyTAC™ and TicTAC™ platforms toward clinical and regulatory milestones.
0
0
0
This Saturday is #WorldBloodDonorDay. Cancer patients, especially those with blood cancers like #CMML, use nearly 25% of the U.S. blood supply each year, but only 3% of Americans donate. If you're eligible, consider learning how to help:
0
0
0
We’re excited to welcome Jennifer O’Neil, PhD, as Solu’s new SVP of Biology! A proven leader in drug discovery and translational science, Jennifer brings deep cross-modality experience that will help advance our platform for patients with hematologic malignancies. Welcome!
0
0
0
For #NationalCancerResearchMonth, we're highlighting #CMML—a complex blood cancer that affects the bone marrow and blood cells. At Solu, we're advancing research in CMML alongside groups like @LLSusa to improve options for patients. Learn more:
0
0
0